Open an account

Haleon

HLN · LONDON

$10.27−$0.10 (−0.96%)TodayMarket closed ·
Prev close $10.37

About HLN

Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

Employees
24,000
Headquarters
Weybridge, Surrey
Listed
Jul 18, 2022
Sector
Health Care
Industry
Pharmaceuticals
Website
haleon.com

HLN key statistics

Market cap
33.66B
Price-earnings ratio
0.00
Dividend yield
1.88%
Average volume
17.56M
Volume
15.07M
Open price
$10.30
High today
$10.34
Low today
$10.22
52 Week high
$11.28
52 Week low
$8.65

Haleon (HLN) at a glance

As of Oct 23, 2026, Haleon (HLN) shares are priced at $10.27, giving the company a market cap of 33.66B, a price-to-earnings ratio of 0.00 and a dividend yield of 1.88%.

Today the stock has traded between $10.22 and $10.34. The current price is 0.5% above the day's low and 0.6% below its high.

Volume so far is 15.07M shares, in line with the average of 17.56M shares a day.

Over the past year Haleon has ranged from $8.65 to $11.28, and now sits 62% of the way up that range.

Haleon met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q4 FY24 it reported $0.0432 per share against an estimate of $0.0403.

The average analyst price target is $11.77, 14.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 18 analystsAvg $11.77
Low
$8.69
Now
$10.27
High
$14.51

HLN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 5.8% on average.

  1. Q1 FY23: reported $0.0489 per share against an estimate of $0.054
  2. Q2 FY23: reported $0.0361 per share against an estimate of $0.0969
  3. Q3 FY23: reported $0.0502 per share against an estimate of $0.0474
  4. Q4 FY23: reported $0.0327 per share against an estimate of $0.048
  5. Q1 FY24: reported $0.0516 per share against an estimate of $0.048
  6. Q2 FY24: reported $0.0384 per share against an estimate of $0.0375
  7. Q3 FY24: reported $0.0458 per share against an estimate of $0.0467
  8. Q4 FY24: reported $0.0432 per share against an estimate of $0.0403

HLN news

  • Press releasePRNewswire

    Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore

  • Vandana Singh

    Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report

  • Press releaseBusiness Wire

    Voltaren Arthritis Pain Gel Launches “Ticket to Relief” to Help Golf Fans Keep Moving and Stay in the Game

  • Press releasePRNewswire

    Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes

  • Press releaseBusiness Wire

    Centrum Reframes Healthy Aging as a Proactive Practice for Adults 35 and Beyond

  • Press releasePRNewswire

    Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes

  • Press releaseBusiness Wire

    Emergen-C Declares Itself the Drink of the Summer Through New Partnership with Carl Radke's Soft Bar Making Everyday Wellness A Refreshing Summer Ritual

  • Press releaseBusiness Wire

    Sensodyne Clinical Repair & Michelle Buteau Put Sensitive Teeth to the Test with the World’s Coldest Treat

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.